Literature DB >> 10747763

A comparative review of generic quality-of-life instruments.

S J Coons1, S Rao, D L Keininger, R D Hays.   

Abstract

The assessment of health-related quality of life (HR-QOL) is an essential element of healthcare evaluation. Hundreds of generic and specific HR-QOL instruments have been developed. Generic HR-QOL instruments are designed to be applicable across a wide range of populations and interventions. Specific HR-QOL measures are designed to be relevant to particular interventions or in certain subpopulations (e.g. individuals with rheumatoid arthritis). This review examines 7 generic HR-QOL instruments: (i) the Medical Outcomes Study 36-Item Short Form (SF-36) health survey; (ii) the Nottingham Health Profile (NHP); (iii) the Sickness Impact Profile (SIP); (iv) the Dartmouth Primary care Cooperative Information Project (COOP) Charts; (v) the Quality of Well-Being (QWB) Scale; (vi) the Health Utilities Index (HUI); and (vii) the EuroQol Instrument (EQ-5D). These instruments were selected because they are commonly used and/or cited in the English language literature. The 6 characteristics of an instrument addressed by this review are: (i) conceptual and measurement model; (ii) reliability; (iii) validity; (iv) respondent and administrative burden; (v) alternative forms; and (vi) cultural and language adaptations. Of the instruments reviewed, the SF-36 health survey is the most commonly used HR-QOL measure. It was developed as a short-form measure of functioning and well-being in the Medical Outcomes Study. The Dartmouth COOP Charts were designed to be used in everyday clinical practice to provide immediate feedback to clinicians about the health status of their patients. The NHP was developed to reflect lay rather than professional perceptions of health. The SIP was constructed as a measure of sickness in relation to impact on behaviour. The QWB, HUI and EQ-5D are preference-based measures designed to summarise HR-QOL in a single number ranging from 0 to 1. We found that there are no uniformly 'worst' or 'best' performing instruments. The decision to use one over another, to use a combination of 2 or more, to use a profile and/or a preference-based measure or to use a generic measure along with a targeted measure will be driven by the purpose of the measurement. In addition, the choice will depend on a variety of factors including the characteristics of the population (e.g. age, health status, language/culture) and the environment in which the measurement is undertaken (e.g. clinical trial, routine physician visit). We provide our summary of the level of evidence in the literature regarding each instrument's characteristics based on the review criteria. The potential user of these instruments should base their instrument selection decision on the characteristics that are most relevant to their particular HR-QOL measurement needs.

Entities:  

Mesh:

Year:  2000        PMID: 10747763     DOI: 10.2165/00019053-200017010-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  97 in total

1.  Using health status measures in the hospital setting: from acute care to 'outcomes management'.

Authors:  D Lansky; J B Butler; F T Waller
Journal:  Med Care       Date:  1992-05       Impact factor: 2.983

Review 2.  Multi-attribute preference functions. Health Utilities Index.

Authors:  G W Torrance; W Furlong; D Feeny; M Boyle
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

3.  Methods for assessing condition-specific and generic functional status outcomes after total knee replacement.

Authors:  M E Kantz; W J Harris; K Levitsky; J E Ware; A R Davies
Journal:  Med Care       Date:  1992-05       Impact factor: 2.983

4.  Valuation of health states by the general public: feasibility of a standardized measurement procedure.

Authors:  M L Essink-Bot; G J Bonsel; P J van der Maas
Journal:  Soc Sci Med       Date:  1990       Impact factor: 4.634

5.  Use of the EuroQoL among elderly acute care patients.

Authors:  J Coast; T J Peters; S H Richards; D J Gunnell
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

6.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

7.  Test-retest reliability of health state valuations collected with the EuroQol questionnaire.

Authors:  H M van Agt; M L Essink-Bot; P F Krabbe; G J Bonsel
Journal:  Soc Sci Med       Date:  1994-12       Impact factor: 4.634

8.  Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial.

Authors:  C Bombardier; J Ware; I J Russell; M Larson; A Chalmers; J L Read
Journal:  Am J Med       Date:  1986-10       Impact factor: 4.965

Review 9.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

10.  Weights for scoring the quality of well-being instrument among rheumatoid arthritics. A comparison to general population weights.

Authors:  D J Balaban; P C Sagi; N I Goldfarb; S Nettler
Journal:  Med Care       Date:  1986-11       Impact factor: 2.983

View more
  196 in total

Review 1.  A review of health-related quality-of-life measures in stroke.

Authors:  B A Golomb; B G Vickrey; R D Hays
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.

Authors:  Nick Kontodimopoulos
Journal:  Qual Life Res       Date:  2014-11-13       Impact factor: 4.147

3.  Towards more consistent use of generic quality-of-life instruments.

Authors:  Mattias Neyt
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Health state preferences are equivalent in the United States and Trinidad and Tobago.

Authors:  Richard D Hector; John P Anderson; Rosemarie C P Paul; Robert E Weiss; Ron D Hays; Robert M Kaplan
Journal:  Qual Life Res       Date:  2010-03-17       Impact factor: 4.147

5.  Validity of EQ-5D in general population of Taiwan: results of the 2009 National Health Interview and Drug Abuse Survey of Taiwan.

Authors:  Sheng-Tsung Yu; Hsing-Yi Chang; Kai-Ping Yao; Yu-Hsuan Lin; Baai-Shyun Hurng
Journal:  Qual Life Res       Date:  2015-04-02       Impact factor: 4.147

6.  Validation of the EQ-5D quality of life instrument in patients after myocardial infarction.

Authors:  David Nowels; Joe McGloin; John M Westfall; Sherry Holcomb
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

7.  OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Authors:  Joanna C Robson; Gunnar Tomasson; Nataliya Milman; Sue Ashdown; Annelies Boonen; George C Casey; Peter F Cronholm; David Cuthbertson; Jill Dawson; Haner Direskeneli; Ebony Easley; Tanaz A Kermani; John T Farrar; Don Gebhart; Georgia Lanier; Raashid A Luqmani; Alfred Mahr; Carol A McAlear; Jacqueline Peck; Beverley Shea; Judy A Shea; Antoine G Sreih; Peter S Tugwell; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

8.  The life control scale: validation with a population cohort of middle-aged Australian women.

Authors:  Christina Lee; Jess Ford; Helen Gramotnev
Journal:  Int J Behav Med       Date:  2009-02-24

9.  Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life.

Authors:  Farshad Nassiri; Benjamin Price; Ameer Shehab; Karolyn Au; Michael D Cusimano; Michael D Jenkinson; Christine Jungk; Alireza Mansouri; Thomas Santarius; Suganth Suppiah; Ken X Teng; Gurvinder S Toor; Gelareh Zadeh; Tobias Walbert; Katharine J Drummond
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 10.  A review of quality of life instruments used in liver transplantation.

Authors:  Colleen L Jay; Zeeshan Butt; Daniela P Ladner; Anton I Skaro; Michael M Abecassis
Journal:  J Hepatol       Date:  2009-07-28       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.